冠心病患者血清成纤维细胞生长因子21和核转录过氧化物酶增殖体激活受体γ水平变化及临床意义  

Changes and clinical significance of serum fibroblast growth factor 21 and nuclear peroxisome proliferator-activated receptor γ levels in patients with coronary heart disease

作　　者：林朴卿 洪长江 吴珊 胡中志 LIN Puqing;HONG Changjiang;WU Shan;HU Zhongzhi(Department of Cardiology,Clifford Hospital of Guangzhou University of Chinese Medicine,Guangdong Province,Guangzhou 511495,China)

机构地区：[1]广州中医药大学祈福医院心内科,广东广州511495

出　　处：《中国医药导报》2020年第17期67-70,共4页China Medical Herald

基　　金：广东省医学科研基金项目(A2017079)。

摘　　要：目的探讨冠心病(CHD)患者血清成纤维细胞生长因子21(FGF21)、核转录过氧化物酶增殖体激活受体γ(PPARγ)水平变化及临床意义。方法选择2018年3月~2019年3月广州中医药大学祈福医院(以下简称"我院")住院接受治疗的由冠脉造影确诊为CHD患者129例作为观察组,选取同期来我院健康体检的体检者80名作为对照组。根据冠脉病变程度将观察组分为轻度组(n=45)、中度组(n=55)和重度组(n=29);根据冠脉病变分支数量将观察组分为单支病变组(n=48)、双支病变组(n=44)和多支病变组(n=37)。采用酶联免疫吸附试验法检测各组血清FGF21和PPARγ水平,并分析FGF21和PPARγ水平与Gensini评分及病变支数的关系。结果观察组血清FGF21和PPARγ水平均显著高于对照组,差异均有统计学意义(均P <0.05)。CHD不同程度冠脉病变患者中,中度组的FGF21和PPARγ水平均高于轻度组,而重度组高于中度组和轻度组,差异均有统计学意义(均P <0.05)。CHD不同程度冠脉病变支数患者中,双支病变组的FGF21和PPARγ水平均高于单只病变组,而多支病变组均高于双支病变组和单只病变组,差异均有统计学意义(均P <0.05)。Spearman相关性分析发现,CHD患者中FGF21和PPARγ水平与病变支数和Gensini评分呈正相关(r> 0,P <0.05),FGF21水平与PPARγ水平呈正相关(r> 0,P <0.05)。结论 CHD患者血清FGF21和PPARγ水平上升,且FGF21和PPARγ水平与冠脉病变狭窄程度及病变累积密切相关。Objective To investigate the changes and clinical significance of serum fibroblast growth factor 21(FGF21 and nuclear peroxisome proliferator-activated receptorγ(PPARγ)levels in patients with coronary heart disease(CHD).Methods A total of 129 patients with CHD confirmed by coronary angiography during hospitalization in Clifford Hospital of Guangzhou University of Chinese Medicine(hereinafter referred to as"our hospital")from March 2018 to March2019 were selected as the observation group,and 80 person who came to our hospital for physical examination during the same period were selected as the control group.The observation group was divided into mild group(n=45),moderate group(n=55)and severe group(n=29)according to the degree of coronary artery disease.The observation group was divided into single-vessel lesion group(n=48),double-vessel lesion group(n=44)and multi-vessel lesion group(n=37)according to the number of coronary artery lesion branches.Serum FGF21 and PPARγlevels in each group were determined by enzyme-linked immunosorbent assay,and the relationship between FGF21 and PPARγlevels and Gensini score and lesion count was analyzed.Results Serum FGF21 and PPARγlevels of patients in the observation group were significantly higher than those in the control group,and the differences were statistically significant(all P<0.05).Among the CHD patients with different degrees of coronary artery disease,the FGF21 and PPARγlevels in the moderate group were higher than those in the mild group,while those in the severe group were higher than those in the moderate group and the mild group,with statistically significant differences(all P<0.05).Among the CHD patients with varying degrees of coronary artery lesions,the FGF21 and PPARγlevels in the double-vessel lesion group were higher than those in the single-vessel lesion group,while those in the multiple-vessel lesion group were higher than those in the double-vessel lesion group and the single-vessel lesion group,with statistically significant differences(all P<0.

关 键 词：冠心病 血清成纤维细胞生长因子21 核转录过氧化物酶增殖体激活受体γ GENSINI评分 

分 类 号：R541.4[医药卫生—心血管疾病]